{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T17:39:30Z","timestamp":1781631570185,"version":"3.54.5"},"reference-count":23,"publisher":"Wiley","issue":"1","license":[{"start":{"date-parts":[[2017,4,11]],"date-time":"2017-04-11T00:00:00Z","timestamp":1491868800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Hematological Oncology"],"published-print":{"date-parts":[[2018,2]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Castleman disease is a rare lymphoproliferative disorder with 2 distinctly defined clinical forms. While multicentric Castleman disease (UCD) poses a potential therapeutic challenge, unicentric variant has historically been considered curable with surgical resection. Hence, little is known to guide management of patients with UCD, refractory to surgical resection and combination chemotherapy. We present a case of a patient, negative for HIV and HHV\u20108, who had an unsuccessful surgical intervention and no response to radiotherapy and chemotherapy. He had severe paraneoplastic pemphigus and was treated with tocilizumab, an anti\u2010interleukin\u20106 receptor monoclonal antibody that has demonstrated good response rates in multicentric Castleman disease but demonstrated no clinical response despite 2\u00a0months of treatment. Our report is the first to describe a lack of response to tocilizumab in the rare setting of refractory UCD and discuss potential for distinct disease biology.<\/jats:p>","DOI":"10.1002\/hon.2420","type":"journal-article","created":{"date-parts":[[2017,4,12]],"date-time":"2017-04-12T04:12:45Z","timestamp":1491970365000},"page":"320-323","source":"Crossref","is-referenced-by-count":8,"title":["Is tocilizumab a potential therapeutic option for refractory unicentric Castleman disease?"],"prefix":"10.1002","volume":"36","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1128-0445","authenticated-orcid":false,"given":"Muhammad Bilal","family":"Abid","sequence":"first","affiliation":[{"name":"Department of Haematology University Hospitals of Bristol NHS Trust  Bristol UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachel","family":"Peck","sequence":"additional","affiliation":[{"name":"Department of Haematology University Hospitals of Bristol NHS Trust  Bristol UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muhammad Abbas","family":"Abid","sequence":"additional","affiliation":[{"name":"Division of Otolaryngology and Head and Neck Surgery John Hopkins School of Medicine  Baltimore MD USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2901-7979","authenticated-orcid":false,"given":"Wesam","family":"Al\u2010Sakkaf","sequence":"additional","affiliation":[{"name":"Department of Haematology University Hospitals of Bristol NHS Trust  Bristol UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuening","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Cellular Pathology University Hospitals Bristol NHS Trust  Bristol UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giles S.","family":"Dunnill","sequence":"additional","affiliation":[{"name":"Department of Dermatology University Hospitals of Bristol NHS Trust  Bristol UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Konrad","family":"Staines","sequence":"additional","affiliation":[{"name":"Department of Oral Medicine University Hospitals of Bristol NHS Trust  Bristol UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Iara\u2010Maria","family":"Sequeiros","sequence":"additional","affiliation":[{"name":"Department of Radiology University Hospitals of Bristol NHS Trust  Bristol UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa","family":"Lowry","sequence":"additional","affiliation":[{"name":"Department of Haematology University Hospitals of Bristol NHS Trust  Bristol UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2017,4,11]]},"reference":[{"key":"e_1_2_8_2_1","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(195607\/08)9:4<822::AID-CNCR2820090430>3.0.CO;2-4"},{"key":"e_1_2_8_3_1","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-128-8-199804150-00010"},{"key":"e_1_2_8_4_1","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1097-0142(19990201)85:3<706::AID-CNCR21>3.0.CO;2-7"},{"key":"e_1_2_8_5_1","doi-asserted-by":"publisher","DOI":"10.1080\/10428190903060095"},{"key":"e_1_2_8_6_1","doi-asserted-by":"publisher","DOI":"10.1097\/SLA.0b013e318249dcdc"},{"key":"e_1_2_8_7_1","doi-asserted-by":"publisher","DOI":"10.1038\/modpathol.2013.202"},{"key":"e_1_2_8_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(04)15539-6"},{"key":"e_1_2_8_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cancergen.2011.04.003"},{"key":"e_1_2_8_10_1","doi-asserted-by":"publisher","DOI":"10.1097\/BOR.0b013e32834db525"},{"key":"e_1_2_8_11_1","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2015.00625"},{"issue":"7","key":"e_1_2_8_12_1","first-page":"717","article-title":"Interleukin 6 in autoimmune and inflammatory diseases: a personal memoir. Proceedings of the Japan Academy","volume":"86","author":"Hirano T","year":"2010","journal-title":"Ser B Phys Biol Sci"},{"key":"e_1_2_8_13_1","doi-asserted-by":"publisher","DOI":"10.2147\/JBM.S60514"},{"key":"e_1_2_8_14_1","doi-asserted-by":"publisher","DOI":"10.1378\/chest.09-2084"},{"issue":"3","key":"e_1_2_8_15_1","first-page":"265","article-title":"Intensity modulated radiation therapy (IMRT) for the treatment of unicentric Castlemans disease: a case report and review of the use of radiotherapy in the literature","volume":"46","author":"Matthiesen C","year":"2012","journal-title":"Radiother Oncol"},{"key":"e_1_2_8_16_1","doi-asserted-by":"publisher","DOI":"10.1172\/JCI114749"},{"key":"e_1_2_8_17_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-09-377705"},{"key":"e_1_2_8_18_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2004-12-4602"},{"key":"e_1_2_8_19_1","doi-asserted-by":"publisher","DOI":"10.2169\/internalmedicine.46.6262"},{"key":"e_1_2_8_20_1","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.MCT-11-0972"},{"key":"e_1_2_8_21_1","doi-asserted-by":"publisher","DOI":"10.1186\/1756-8722-7-10"},{"key":"e_1_2_8_22_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.13378"},{"key":"e_1_2_8_23_1","doi-asserted-by":"publisher","DOI":"10.1097\/MPH.0b013e3182352dc7"},{"key":"e_1_2_8_24_1","doi-asserted-by":"publisher","DOI":"10.1186\/1748-717X-5-7"}],"container-title":["Hematological Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fhon.2420","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/hon.2420","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,24]],"date-time":"2023-09-24T10:56:40Z","timestamp":1695553000000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/hon.2420"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,4,11]]},"references-count":23,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2018,2]]}},"alternative-id":["10.1002\/hon.2420"],"URL":"https:\/\/doi.org\/10.1002\/hon.2420","archive":["Portico"],"relation":{},"ISSN":["0278-0232","1099-1069"],"issn-type":[{"value":"0278-0232","type":"print"},{"value":"1099-1069","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,4,11]]}}}